Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
Journal: Cancer 20120415
Title: Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Journal: Journal of hematology & oncology 20120101
Title: Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
Journal: Journal of hematology & oncology 20120101
Title: Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
Journal: Seminars in oncology 20111001
Title: Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor.
Journal: Journal of hematology & oncology 20110101
Title: Novel therapies for myelodysplastic syndromes.
Journal: Hematology/oncology clinics of North America 20100401
Title: Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.
Journal: Journal of hematology & oncology 20100101
Title: Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.
Journal: Blood 20090625
Title: Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
Journal: Journal of hematology & oncology 20090101
Title: Treatment of MDS: something old, something new, something borrowed..
Journal: Hematology. American Society of Hematology. Education Program 20090101
Title: Developmental therapeutics for myelodysplastic syndromes.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN 20060101
Title: TLK-199 (Telik).
Journal: IDrugs : the investigational drugs journal 20050801
Title: Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid.
Journal: Gastroenterology 20040801
Title: Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways.
Journal: The Journal of pharmacology and experimental therapeutics 20010701
Title: Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20
Title: Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298(1):339-45.
